Skip to main content
. 2022 Oct 19;10(10):2635. doi: 10.3390/biomedicines10102635

Figure 2.

Figure 2

Evolution of asthma control measured by the Asthma Control Test (ACT) in subjects with severe refractory asthma with the eosinophilic–allergic phenotype, before and after 52-week treatment with mepolizumab 100 mg every 4 weeks. Asterisks indicate statistical significance (**** p < 0.001).